BrainStorm Leadership to Showcase Innovations at DUPHAT 2026 Conference

BrainStorm Cell Therapeutics Inc., renowned for its advanced cell therapies targeting neurodegenerative conditions, is gearing up to participate in the highly anticipated Dubai International Pharmaceuticals and Technologies Conference and Exhibition (DUPHAT) from August 25 to 27, 2026. This event, hosted at the Dubai World Trade Centre, brings together industry professionals, researchers, and regulators from over 100 countries, creating a global platform for discussion and innovation in healthcare.

Keynote Presentations and Expert Panel Moderation

The spotlight will shine on Peter J. Pitts, BrainStorm's Executive Chairman and former FDA Associate Commissioner, who has been invited to deliver two significant keynote addresses. His presentations will cover:

1. Establishing an FDA Abraham Accords Office: A deep dive into creating a coherent regulatory policy framework aimed at harmonizing clinical trial processes and therapeutic approvals across the Middle East and international markets.
2. Rethinking NIH Grants: An innovative approach to reconstruct public research funding models designed to enhance collaboration between academic institutions, biotechnology developers, and commercial stakeholders.

In addition to his keynotes, Pitts will lead expert discussions focusing on crucial topics such as Translational Pharmaceutical Innovation, where he will moderate a panel aimed at accelerating the journey from laboratory research to commercial viability in patient care. Another vital session will address the Emerging Roles of Pharmacists, exploring the expanding responsibilities of pharmacists in modern healthcare delivery and their role in the management of biopharmaceuticals.

Strategic Meetings and Global Partnerships

Alongside the conference activities, the executive team at BrainStorm, including President and CEO Chaim Lebovits, will engage in strategic meetings with regional health regulators and potential commercial partners. These discussions are crucial as the company seeks to position its innovative therapy, NurOwn®, strategically and prepare for the upcoming Phase 3b ENDURANCE trial under a Special Protocol Assessment with the U.S. FDA.

Chaim Lebovits expressed confidence in the potential outcomes of these engagements, stating, "Peter's invitations highlight our commitment to maintaining a leading role in regulatory policy and health system innovation. Engaging with key stakeholders at DUPHAT will strengthen our global presence and pave the way for strategic partnerships across the Middle East."

The Significance of DUPHAT

DUPHAT has been a cornerstone event in the pharmaceutical and biotechnology sectors for over three decades. This annual gathering accommodates more than 31,000 healthcare professionals, including health ministers, regulatory officials, and biopharmaceutical executives, making it an unparalleled opportunity for networking and collaboration. The conference includes a multifaceted scientific program dedicated to advancing drug development and fostering international regulatory alignment.

About NurOwn®

At the heart of BrainStorm's innovations is the NurOwn® platform, which utilizes autologous mesenchymal stem cells to generate therapeutic cells capable of delivering crucial neurotrophic factors directly to damaged areas. This investigational therapy stands as BrainStorm's lead candidate for amyotrophic lateral sclerosis (ALS) treatment, having achieved Orphan Drug designation from both the FDA and the European Medicines Agency (EMA). Following promising results from Phase 3 trials, the company is preparing for its next phase of trials, intending to further explore the therapeutic benefits of NurOwn.

Conclusion

BrainStorm Cell Therapeutics remains at the forefront of innovative solutions for neurodegenerative diseases. Their participation in DUPHAT 2026 not only underscores their commitment to transforming healthcare but also highlights the collaborative efforts needed to address the complexities of the pharmaceutical landscape. As the company progresses toward its clinical goals, engagement at this level signifies its intent to drive meaningful advancements in patient care and therapeutic development on a global scale.